OTC · VAXX
Healthcare · Biotechnology
$0.00
Up+$0.00 (+0.00%)
Updated Oct 7, 2026, 3:54 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · VAXX
1M range · 0 trading sessions · Daily adjusted prices
VAXX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning VAXX.
Company
Market Activity
Research & News
VAXX research
Company profile and research snapshot.
VAXXINITY INC A
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2023 | Baird | Outperform | — |
| Apr 27, 2022 | Evercore ISI Group | In-Line | — |
| Dec 7, 2021 | Jefferies | Buy | — |
| Dec 6, 2021 | B of A Securities | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jun 20, 2024
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living.
GlobeNewswire Inc. · Apr 19, 2024
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu.
GlobeNewswire Inc. · Apr 19, 2024
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market (“Nasdaq”) and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Section 15(d) of the Exchange Act.
GlobeNewswire Inc. · Mar 28, 2024
Presentation will address the Company’s clinical data in Parkinson’s disease Presentation will address the Company’s clinical data in Parkinson’s disease
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VAXX.
No results
No recent SID articles mention VAXX.
